SCHEMBL1475337

SCHEMBL1475337

O=C(NCCc1cccnc1)c1cc(-c2cccc(C(F)(F)F)c2)on1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.59
KMT2A Q03164 3/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
MAPT P10636 3/20 0.57
FAAH O00519 4/20 0.56
CYP1A2 P05177 2/20 0.55
CYP3A4 P08684 2/20 0.55
CYP2C19 P33261 2/20 0.55
CYP2D6 P10635 1/20 0.55
CYP2C9 P11712 1/20 0.55
NPC1 O15118 3/20 0.53
TP53 P04637 2/20 0.53
LMNA P02545 2/20 0.53
POLB P06746 1/20 0.53
PKM P14618 2/20 0.52
HPGD P15428 2/20 0.52
KDM4E B2RXH2 2/20 0.51
MEN1 O00255 2/20 0.51
HSD17B10 Q99714 2/20 0.51
SIGMAR1 Q99720 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1474720 0.90 FAAH (0.70) RAB9AKMT2ASMN1; SMN2MAPTFAAH
SCHEMBL1474570 0.89 FAAH (0.62) RAB9ASMN1; SMN2MAPTFAAHCYP1A2
SCHEMBL1474381 0.87 RAB9A (0.62) RAB9AKMT2ASMN1; SMN2MAPTFAAH
SCHEMBL1476381 0.86 RAB9A (0.63) RAB9AKMT2ASMN1; SMN2MAPTFAAH
SCHEMBL1475308 0.85 RAB9A (0.79) RAB9AKMT2ASMN1; SMN2MAPTFAAH
SCHEMBL15190505 0.85 CYP3A4 (0.52) RAB9AKMT2ASMN1; SMN2MAPTFAAH
SCHEMBL1475553 0.85 RAB9A (0.62) RAB9AKMT2ASMN1; SMN2MAPTFAAH
SCHEMBL1475220 0.83 FAAH (0.65) RAB9AKMT2ASMN1; SMN2FAAHCYP1A2
SCHEMBL1475551 0.82 ALDH1A1 (0.60) RAB9AKMT2ASMN1; SMN2MAPTFAAH
SCHEMBL1473795 0.81 FAAH (0.66) RAB9AKMT2ASMN1; SMN2MAPTFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131336-A1 Isoxazole Derivatives and Use Thereof WNT3A, WNT1, WNT3 RAB9A 2013/4885KMT2A 4661/4885SMN1; SMN2 3980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.